Naf arelin in the Treatment of Endometriosis

Hull, Magdalen E.; Barbieri, Robert L.

doi:10.1159/000292574

Cited by 7 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 1664 records screened, 14 studies regarding clinical outcomes associated with the three considered alternative modalities for GnRH agonist use were eventually included: intermittent oestrogen deprivation therapy, n = 2 ( Adamson et al , 1997 ; Hornstein et al , 1997 ); low-dose or ‘draw-back’ therapy, n = 8 ( Hull and Barbieri, 1994 ; Jacobson et al , 1994 ; Bergqvist et al , 1997 ; Uemura et al , 1999 ; Tahara et al , 2000 ; Akira et al , 2009 ; Tang et al , 2017 ; Harada et al , 2022 ); and extended-interval dosing regimen, n = 4 ( Tse et al , 2000 ; Wong and Tang, 2004 ; Kang et al , 2010 ; Liu et al , 2016 ). Six studies were RCTs (double blind, n = 2), whereas eight adopted a prospective cohort design (non-comparative, n = 6; comparative, n = 2).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not?

Vercellini

Bandini

Buggio

et al. 2023

Human Reproduction Open

View full text Add to dashboard Cite

STUDY QUESTION Is it possible to reduce the cost of GnRH agonist treatment for endometriosis by using non-standard dosing regimens? SUMMARY ANSWER An extended-interval dosing regimen of a 3.75 mg depot formulation of triptorelin injected every 6 weeks instead of every 4 weeks reduces the cost by one-third without compromising the effect on pain relief. WHAT IS KNOWN ALREADY Cost constitutes a limit to prolonged GnRH agonists use. Alternative modalities to reduce the economic burden of GnRH agonist treatment have been anecdotally attempted. STUDY DESIGN, SIZE, DURATION A systematic review was conducted to evaluate and compare the effect of three alternative modalities for GnRH use in women with endometriosis, i.e. intermittent oestrogen deprivation therapy, reduced drug dosage, and extended-interval dosing regimens of depot formulations. A PubMed and Embase search was initially conducted in October 2022 and updated in January 2023 using the following search strings: (endometriosis OR adenomyosis) AND (GnRH-agonists OR gonadotropin-releasing hormone agonists OR triptorelin OR leuprorelin OR goserelin OR buserelin OR nafarelin). Full-length articles published in English in peer-reviewed journals since 1 January 1980, and reporting original data on GnRH agonist treatment of pain symptoms associated with endometriosis were selected. PARTICIPANTS/MATERIALS, SETTING, METHODS Information was extracted on study design, GnRH-agonist used, dosage, total duration of therapy, side effects, treatment adherence, and pelvic pain relief. Reviews, commentaries, conference proceedings, case reports, and letters to the editor were excluded. MAIN RESULTS AND THE ROLE OF CHANCE Of the 1664 records screened, 14 studies regarding clinical outcomes associated with the 3 considered alternative modalities for GnRH agonist use were eventually included (intermittent oestrogen deprivation therapy, n = 2; low-dose or ‘draw-back’ therapy, n = 8; extended-interval dosing regimen, n = 4). Six studies were randomized controlled trials (RCTs) (double blind, n = 2) and eight adopted a prospective cohort design (non-comparative, n = 6; comparative, n = 2). A total of 776 women with endometriosis were recruited in the above studies (intermittent oestrogen deprivation therapy, n = 77; low-dose or ‘draw-back’ therapy, n = 528; extended-interval dosing regimen, n = 171). Robust data demonstrating cost saving without detrimental clinical consequences were available for the extended-interval dosing regimen only. In particular, the 3.75 mg triptorelin depot preparation inhibits ovarian function for a longer period compared with the 3.75 mg leuprorelin depot preparation, allowing injections every 6 instead of 4 weeks. Based on the cost indicated by the Italian Medicine Agency for the 3.75 mg triptorelin depot preparation, this would translate in a yearly saving of €744.60 (€2230.15–€1485.55; −33.4%). LIMITATIONS, REASONS FOR CAUTION The quality of the evidence reported in the selected articles was not formally evaluated and a quantitative synthesis could not be performed. Some studies were old and the tested therapeutic approaches were apparently obsolete. Only cost containment associated with GnRH analogue use, and not cost-effectiveness, has been addressed. WIDER IMPLICATIONS OF THE FINDINGS Consuming less resources without negatively impacting on health outcomes carries ethical and practical implications for individuals and the community, as this approach may result in overall increased healthcare access. STUDY FUNDING/COMPETING INTEREST(S) This study was supported by the Italian Ministry of Health (Ricerca Corrente 2023, IRCCS Ca' Granda Ospedale Maggiore Policlinico Milano). E.S. discloses payments from Ferring for research grants and honoraria from Merck-Serono for lectures. All other authors declare they have no conflict of interest. REGISTRATION NUMBER N/A.

show abstract

Section: Resultsmentioning

confidence: 99%

“…In 1994, Hull and Barbieri (1994) were the first to alter a GnRH agonist dosage guided by serum E2 concentrations to limit pain symptom recurrence while mitigating oestrogen deprivation effects. They treated 23 women with endometriosis with intranasal nafarelin starting at the usual dosage of 400 µg/day (200 µg b.i.d.).…”

Section: Resultsmentioning

confidence: 99%